<DOC>
	<DOCNO>NCT01880632</DOCNO>
	<brief_summary>1 . Target population : locally advance gastric adenocarcinoma ( LAGC , cT2~3/N+M0 , cT4aN+M0 ) ; previous chemo radio therapy . 2 . Primary objective : Response rate XELOX neoadjuvant set LAGC . Secondary objective : - The progression free survival ( PFS ) perioperative treatment locally advance gastric adenocarcinoma ( cT3/N+M0 , cT4aN+M0 ) ; - percentage pathological response ; percentage grade 3 4 adverse event safety profile perioperative treatment ; - D2 resection -rate neoadjuvant chemotherapy XELOX ; - Overall survival ; - QOL whole period treatment . 3 . Trial design : This multicenter , single arm , open-label , phase II study evaluate efficacy safety Oxaliplatin plus capecitabine ( XELOX ) perioperative treatment locally advance gastric adenocarcinoma combination D2 resection . 4 . Treatment plan : Patients give perioperative chemotherapy recruit : Schedule Oxaliplatin plus capecitabine ( XELOX ) follow : Capecitabine 1000 mg/m2 ，bid , 1~14 every 3 week ( treatment 2 week rest 1 week ) Oxaliplatin：130mg/m2， iv infusion 2h，d1 , every 3 week . 5 . Number subjects:50 patients.Number center 5 site , high volume gastric operation China , 500 per year .</brief_summary>
	<brief_title>Oxaliplatin Plus Capecitabine Perioperative Treatment Locally Advanced Gastric Adenocarcinoma</brief_title>
	<detailed_description>1 . Disease specific inclusion criterion : - Histologically document gastricadenocarcinoma Lauren classification Clinically diagnose stage T2-3/N+M0 , orT4aN+M0 accord CT/MRI scan , resectable - Measurable disease require - Karnofsky score 80 % . - Physical condition adequate organ function ensure success abdominal surgery . - Life expectancy ≥12 week . - Adequate hematological function : Neutrophil count ≥ 1.5 × 109/L , Platelets ≥ 100 × 109/L Hemoglobin ≥8g/dL .Adequate liver function : Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) ; AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 × ULN absence liver metastasis , &lt; 5 × ULN case liver metastasis . ALP ≤ 2.5 × upper limit normal ( ULN ) ; ALB ≥30g/L . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . - Female subject pregnant breast-feeding . - No serious concomitant disease threaten survival patient le 5 year . 2 . General inclusion criterion : - Male female . Age ≥ 18 year ≤75 year - Written ( sign ) inform consent . - Able comply study follow-up procedure . - Good compliance treatment plan。 - Consent provide tissue sample。</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically document gastricadenocarcinoma Lauren classification Clinically diagnose stage T23/N+M0 , orT4aN+M0 accord CT/MRI scan , resectable Measurable disease require Karnofsky score 80 % . Physical condition adequate organ function ensure success abdominal surgery . Life expectancy ≥12 week . Adequate hematological function : Neutrophil count ≥ 1.5 × 109/L , Platelets ≥ 100 × 109/L Hemoglobin ≥8g/dL .Adequate liver function : Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) ; AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 × ULN absence liver metastasis , &lt; 5 × ULN case liver metastasis . ALP ≤ 2.5 × upper limit normal ( ULN ) ; ALB ≥30g/L.Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . Female subject pregnant breastfeeding . No serious concomitant disease threaten survival patient le 5 year . Male female . Age ≥ 18 year ≤75 year Written ( sign ) inform consent . Able comply study followup procedure . Good compliance treatment plan . Consent provide tissue sample . Pregnant lactating ( case potentially childbearing woman , pregnancy test positive ) Patients childbearing age potential father child refuse use adequate contraception Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator . History another malignancy last 5 year exception follow : Any previous palliative , adjuvant neoadjuvant chemotherapy and/or radiotherapy . Prior treatment locally advance metastatic gastric cancer . Any metastatic disease render patient ineligible accord AJCC stag manual . Distant metastasis ( M1 ) include distant nodal Groups ( peripancreatic , paraaortic , portal , retroperitoneal , mesenteric node , CT/MRI , PET/CT Treatment within last 30 day investigational drug . Concurrent administration cancer therapy , include cytotoxic chemotherapy , hormonal therapy , immunotherapy . Active infection opinion investigator would compromise patient 's ability tolerate therapy . Poorly control diabetes mellitus fast blood sugar &gt; 18 mM . Second primary malignancy clinically detectable time consideration study enrollment . History significant neurological mental disorder , include seizure dementia , would interfere compliance sign consent inform . history hypersensitivity 5fluorouracil platinum investigational drug Ileus , chronic inflammatory intestinal disease extensive resection small intestine disorder limit drug reabsorption . This include gastric dump syndrome , indication accelerate passage small intestine , indication reabsorption disorder intestinal surgery Unstable , persistent cardiac disease despite medicinal treatment , myocardial infarction within 6 month start trial Organ transplant patient need immunosuppression treatment . Previous surgery primary tumour ; Prior palliative surgery ( open closure , passage operation ) Any type tumour ( e.g . leiomyosarcoma , lymphoma ) secondary malignancy , except basal cell skin carcinoma basal cell carcinoma situ cervix already successfully treat Symptomatic peripheral neuropathy NCI CTC version &gt; 3.0 grade . Patients anticoagulant therapy warfarin coumarines exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>XELOX</keyword>
	<keyword>perioperative treatment</keyword>
	<keyword>locally advanced gastric adenocarcinoma</keyword>
	<keyword>D2 resection</keyword>
</DOC>